Clinical Trial Update: Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and biomarkers of Adebelizumab in combination with liposomal irinotecan as a second-line treatment for advanced s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Adebelizumab (Adebelizumab)
• Irinotecan liposome (liposomal irinotecan)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING